Opinion|Videos|August 8, 2024
Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC
The panel discusses treatment considerations for consolidation durvalumab.
Advertisement
Episodes in this series
How do you select patients for consolidation durvalumab?
Advertisement
Related to this article
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
By finding a way to attack the most important human oncogene, KRAS, the UCSF chemical biologist launched a new era in cancer treatment.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Aglatimagene besadenovec plus EBRT was linked to a 41% lower risk of prostate cancer recurrence or death, alongside durable immune activity.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Japan approved Optune Pax plus gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
Revisit Every OncLive On Air Episode From September 2026
3
Oral Azacitidine and Cedazuridine Meets Primary Pharmacokinetic End Point in MDS and CMML
4
Optune Pax Is Approved in Japan for Unresectable Locally Advanced Pancreatic Cancer
5